Inflammatory Bowel Disease and COVID-19

Abstract

<jats:p />

Inflammatory Bowel Disease during COVID-19 Pandemic: A Prospective Cohort Study of Incidence Rate and Patients’ Concerns

“…On June 4, 2020, no patient out of the 100 cases recruited in the study acquired COVID-19. 12 Afterward, 10 patients were diagnosed with the confirmed COVID-19 infection during the next follow-ups until December 20, 2020. All the patients had remained in remission before being infected.…”

“…15,16 These findings were comparable to the results of recent studies, 17,18 suggesting that the patients with IBD did not seem to be more susceptible to COVID-19. 19,20 Despite the early time of the pandemic, in which reports were indicative of uneventful COVID-19 in patients with IBD in China and Italy until March, in Greek up to April, and in Iran until June 2020 12,[21][22][23][24] recent studies are increasing on IBD cases affected with the pandemic. 25,26 The comparable incidence of COVID-19 in the patients with IBD and the general population despite receiving immunosuppressants affecting their susceptibility to infection 27 could be the beneficial effect of antiinflammatory medications received on the cytokine storm phase of COVID-19 or acquisition of pneumonia 11,17,[28][29][30] as well as underreporting and underdiagnoses due to the mild course of COVID-19 in the patients with IBD.…”

“… 15 , 16 These findings were comparable to the results of recent studies, 17 , 18 suggesting that the patients with IBD did not seem to be more susceptible to COVID-19. 19 , 20 Despite the early time of the pandemic, in which reports were indicative of uneventful COVID-19 in patients with IBD in China and Italy until March, in Greek up to April, and in Iran until June 2020 12 , 21 - 24 recent studies are increasing on IBD cases affected with the pandemic. 25 , 26 …”

“…[8][9][10][11] While high doses of corticosteroids increase mortality due to COVID-19 in these patients, the use of biologic monotherapy seems to have a protective effect, probably due to the control of cytokine storm-driven inflammation. 12 In a case series from Iran, conducted early in the pandemic, 51 patients with IBD suffering from COVID-19 had been accordingly reported, but the incidence rate had not been specified. 13 To date, there is a paucity of data on the concerns of patients with IBD and the impact of the COVID-19 pandemic on their self-care.…”